Cite
The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey.
MLA
Al-Ezzi, Esmail M., et al. “The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey.” Current Oncology, vol. 30, no. 7, July 2023, pp. 6166–76. EBSCOhost, https://doi.org/10.3390/curroncol30070458.
APA
Al-Ezzi, E. M., Zahralliyali, A., Hansen, A. R., Hamilton, R. J., Crump, M., Kuruvilla, J., Wood, L., Nappi, L., Kollmannsberger, C. K., North, S. A., Winquist, E., Soulières, D., Hotte, S. J., & Jiang, D. M. (2023). The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey. Current Oncology, 30(7), 6166–6176. https://doi.org/10.3390/curroncol30070458
Chicago
Al-Ezzi, Esmail M., Amer Zahralliyali, Aaron R. Hansen, Robert J. Hamilton, Michael Crump, John Kuruvilla, Lori Wood, et al. 2023. “The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey.” Current Oncology 30 (7): 6166–76. doi:10.3390/curroncol30070458.